EUCTR2016-000304-29-GB进行中（未招募）1 期
Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial - POINT, v2.0 28th Jun 2016
MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health0 个研究点目标入组 267 人开始时间: 2016年2月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 267
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient level inclusion criterion:
- •1. 18 years of age or older;
- •Eye level inclusion criteria - at least one eye must meet all of the following conditions
- •2. Non-infectious anterior, intermediate, posterior or panuveitis; either active or inactive uveitis is acceptable;
- •3. Macular edema (ME) defined as the presence of central subfield macular thickness
- •greater than the normal range for the OCT machine being used (>300 µm for Zeiss
- •Cirrus/Topcon 3DOCT or >320 µm for Heidelberg Spectralis), regardless of the
- •presence of cysts, as assessed by study ophthalmologist;
- •4. Best corrected visual acuity (BCVA) 5/200 or better;
- •5. Baseline intraocular pressure > 5 mm Hg and = 21 mm Hg (current use of 3 or fewer intraocular pressure-lowering medications and/or prior glaucoma surgery are acceptable – note that combination medications, i.e., Cosopt, count as 2 IOP lowering medications);
- •6. Baseline fluorescein angiogram that is gradable for degree of leakage in the central subfield
- •7.Pupillary dilation sufficient to allow OCT testing.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Patient level exclusion criteria:
- •1. History of infectious endophthalmitis or infectious uveitis in either eye;
- •2. History of infectious scleritis of any type in either eye. (Note: History of noninfectious scleritis that has been active in past 12 months is an eye-level exclusion –see #11 below.)
- •3. History of keratitis (with the exception of keratitis due to dry eye)of any type in either eye;
- •4.History of central serous retinopathy in either eye;
- •5. For women of childbearing potential: pregnancy, breastfeeding, or a positive pregnancy test; unwilling to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for duration of trial;
- •6. Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline;
- •7. Oral prednisone dose > 10 mg per day (or of an alternative corticosteroid at a dose higher than that equipotent to prednisone 10 mg per day) OR oral prednisone dose = 10 mg per day at baseline that has not been stable for at least 4 weeks (note that if patient is off of oral prednisone at baseline (P01 visit), dose stability requirement for past 4 weeks does not apply);
- •8. Systemic immunosuppressive drug therapy that has not been stable for at least 4 weeks;
- •9. Known allergy or hypersensitivity to any component of the study drugs;
- •Eye level exclusion criteria - at least one eye that meets all inclusion criteria cannot have any of the following conditions:
- •10. History of severe glaucoma as defined by optic nerve damage (cup/disc ratio of = 0.9 or any notching of optic nerve to the rim);
- •11. Media opacity causing inability to assess fundus or perform OCT;
- •12. History of active noninfectious scleritis in past 12 months (Note: History of noninfectious scleritis is acceptable if the last episode of active scleritis resolved at least 12 months prior to enrollment);
- •13. Presence of an epiretinal membrane noted clinically or by OCT that per the judgment of study ophthalmologist may be significant enough to limit improvement of ME (i.e., causing substantial wrinkling of the retinal surface)81;
- •14. Torn or ruptured posterior lens capsule
- •15. Presence of silicone oil;
- •16. Periocular or intravitreal corticosteroid injection in past 8 weeks;
- •17. Injection of dexamethasone intravitreal implant in past 12 weeks;
- •18. Placement of fluocinolone acetonide implant (Retisert) in past 3 years;
研究者
相似试验
已完成
3 期
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema TrialMacular EdemaUveitisNCT02374060JHSPH Center for Clinical Trials192
已完成
3 期
Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular EdemaInflammatory Macular EdemaNCT02556424Nantes University Hospital114
已完成
1 期
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal DisordersDiabetic RetinopathyMacular DegenerationRetinal Vein OcclusionNCT00101764National Eye Institute (NEI)120
尚未招募
4 期
Dexamethasone in Orbital Cellulitis (DOC) TrialACTRN12622000808741South Australian Institute of Ophthalmology128
进行中（未招募）
1 期
Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study - IVMP for ocular pemphigoidocular mucous membrane pemphigoidEUCTR2005-002391-14-GBMoorfields Eye Hospital NHS Foundation Trust20